Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Titan Biotech's share price for the quarter that ended in Mar. 2026 was ₹457.7. Titan Biotech's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 41 Mil. Therefore, Titan Biotech's market cap for the quarter that ended in Mar. 2026 was ₹18,912 Mil.
Titan Biotech's quarterly market cap
increased
from Sep. 2025 (₹7,837 Mil) to Dec. 2025 (₹8,708 Mil) and
increased
from Dec. 2025 (₹8,708 Mil) to Mar. 2026 (₹18,912 Mil).
Titan Biotech's annual market cap
declined
from Mar. 2024 (₹4,365 Mil) to Mar. 2025 (₹3,484 Mil) but then
increased
from Mar. 2025 (₹3,484 Mil) to Mar. 2026 (₹18,912 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Titan Biotech's Enterprise Value for Today is ₹16,605 Mil.
Titan Biotech (BOM:524717) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Titan Biotech Market Cap Related Terms
Titan Biotech Market Cap Historical Data
* Premium members only.
The historical data trend for Titan Biotech's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:524717 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Titan Biotech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Titan Biotech Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Titan Biotech's Market Cap distribution charts can be found below:
* The bar in red indicates where Titan Biotech's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Titan Biotech's Market Cap for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Titan Biotech (BOM:524717) has a Market Cap of ₹16,567 Mil as of Jul. 12, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Titan Biotech and its competitors. According to the industry distribution chart, Titan Biotech ranks #639 out of 1423 companies in the Biotechnology industry, placing it in the top 44.9%.
Is Titan Biotech's Market Cap too high?
Titan Biotech's current Market Cap is ₹16,567 Mil. Based on the distribution chart, Titan Biotech ranks #639 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Titan Biotech has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Titan Biotech's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Titan Biotech ranks #639 out of 1423 companies for Market Cap. This puts Titan Biotech in the upper half of its industry. The industry median Market Cap is 121.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.30, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Titan Biotech and its competitors. For the Biotechnology industry, the median Market Cap is 121.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Titan Biotech's current Market Cap is ₹16,567 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Titan Biotech stock overvalued right now?
Based on GuruFocus' analysis, Titan Biotech (BOM:524717) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹144.74, compared to a current price of ₹400.95 — trading 177% above its estimated fair value. The current Market Cap is ₹16,567 Mil. Titan Biotech's overall GF Score™ is 58/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Titan Biotech (BOM:524717), the current Market Cap is ₹16,567 Mil as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Titan Biotech (BOM:524717) Overvalued in 2026?
Based on GuruFocus' analysis, Titan Biotech stock appears to be overvalued.
The current stock price of ₹400.95 is trading 177% above its estimated GF Value™ of ₹144.74.
GuruFocus considers Titan Biotech to be Significantly Overvalued.
Key valuation signals for BOM:524717:
Market Cap: ₹16,567 Mil
GF Value™: ₹144.74 vs. price of ₹400.95 (177% above fair value)
No single metric tells the full story. See the BOM:524717 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Titan Biotech Ltd is a manufacturer and exporter of biological products. It manufactures biological products such as peptone, malt extract, yeast extract, liver extract, bile extract, culture media, laboratory chemicals, plant growth promoters, and others. The biological products have applications in the field of pharmaceutical, nutraceutical, food and beverages, biotechnology and fermentation, cosmetic, veterinary and animal feed, agriculture industries, and others. The company's business activity falls within a single primary business segment, which is the business of Biological Products. The firm sells its products in India and also exports internationally, of which the majority of the revenue is derived from the sales made in India.
58GF Score
Get the complete analysis for BOM:524717
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524717 has been successfully added to your 
